Table 3.
Steady-state plasma pharmacokinetics of SBECD and voriconazole during CVVH
| SBECD | |||||||
| Cmax (mg/L) | Cmin (mg/L) | T1/2 (hrs) | AUC0-12 (mg*hr/L) | Cl s (L/hr/kg) | Vd (L/kg) | CVVH CL (L/hr/kg) | |
| Mean | 687.0 | 214.5 | 6.3 | 4396 | 0.03 | 0.3 | 0.02 |
| SD | 500.4 | 202.6 | 1.6 | 3325 | 0.02 | 0.2 | 0.01 |
| Median | 561.1 | 165.2 | 6.2 | 3621 | 0.02 | 0.2 | 0.01 |
| 25% | 216.2 | 38.7 | 5.3 | 1352 | 0.01 | 0.1 | 0.01 |
| 75% | 1102.4 | 305.8 | 7.3 | 6804 | 0.05 | 0.4 | 0.02 |
| Voriconazole | |||||||
| Cmax (mg/L) | Cmin (mg/L) | T1/2 (hrs) | AUC0-12 (mg*hr/L) | Cl s (L/hr/kg) | Vd (L/kg) | CVVH CL (L/hr/kg) | |
| Mean | 4.1 | 2.4 | 19.5 | 37 | 0.13 | 3.2 | 0.02 |
| SD | 1.4 | 1.1 | 10.7 | 14 | 0.06 | 1.5 | 0.02 |
| Median | 4.1 | 2.3 | 19.0 | 38 | 0.12 | 2.7 | 0.02 |
| 25% | 3.3 | 2.0 | 13.1 | 30 | 0.09 | 2.1 | 0.01 |
| 75% | 5.1 | 3.0 | 22.5 | 41 | 0.14 | 3.7 | 0.02 |
SBECD, sulfobutylether-β-cyclodextrin; CVVH, continuous venovenous hemofiltration; Cmax, maximum drug concentration in the plasma; Cmin, minimum drug concentration in the plasma; T1/2, half-life; AUC0-12 area under the concentration-time curve from time 0 to 12 hours; Cls, total systemic clearance; Vd, volume of distribution; CVVH CL clearance by continuous venovenous hemofiltration; SD, standard deviation.